Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
IMM-529's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for IMM-529. Showing past 6 months and next 12 months · 2 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| IMM-529 | Immuron | Hyperimmune bovine colostrum (oral) | Phase 2 | 0 | ||||
| Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease | Brigham and Women's Hospital | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence | Benoit Guery | — | Phase 3 | — | — | — | — | — |
| VE303 for Prevention of Recurrent Clostridioides Difficile Infection | Vedanta Biosciences, Inc. | — | Phase 3 | — | — | — | — | — |
| FMT Capsules for rCDI | Helsinki University Central Hospital | — | Phase 3 | — | — | — | — | — |
| Vancomycin Taper to Prevent Recurrent Clostridioides Difficile | McGill University Health Centre/Research Institute of the McGill University Health Centre | — | Phase 3 | — | — | — | — | — |
| Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients | Riverside University Health System Medical Center | — | PHASE2/PHASE3 | — | — | — | — | — |
| LMN-201 for Prevention of C. Difficile Infection Recurrence | Lumen Bioscience, Inc. | — | PHASE2/PHASE3 | — | — | — | — | — |
| Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin | University of Maryland, Baltimore | — | PHASE2/PHASE3 | — | — | — | — | — |
| Secondary Prevention of Clostridioides Difficile Using Vancomycin | McGill University Health Centre/Research Institute of the McGill University Health Centre | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections. | PharmaPlanter Technologies Inc | — | Phase 2 | — | — | — | — | — |
| Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) | University of Virginia | — | Phase 2 | — | — | — | — | — |
| Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | AstraZeneca | — | Phase 2 | — | — | — | — | — |
| ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection | Acurx Pharmaceuticals Inc. | — | Phase 2 | — | — | — | — | — |
| FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — | PHASE1/PHASE2 | — | — | — | — | — |
| Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients | Hospices Civils de Lyon | — | PHASE1/PHASE2 | — | — | — | — | — |